FATE Fate Therapeutics, Inc. Stock Quote

FATE [NASD]

Index	-	P/E	-	EPS (ttm)	-2.35	Insider Own	1.00%	Shs Outstand	94.33M	Perf Week	5.12%
Market Cap	6.02B	Forward P/E	-	EPS next Y	-2.65	Insider Trans	-21.82%	Shs Float	93.52M	Perf Month	1.67%
Income	-212.00M	PEG	-	EPS next Q	-0.58	Inst Own	95.59%	Short Float	12.76%	Perf Quarter	-16.32%
Sales	48.00M	P/S	125.50	EPS this Y	-46.20%	Inst Trans	0.18%	Short Ratio	11.97	Perf Half Y	-21.86%
Book/sh	7.97	P/B	8.55	EPS next Y	-17.80%	ROA	-25.60%	Target Price	109.83	Perf Year	83.84%
Cash/sh	7.87	P/C	8.66	EPS next 5Y	-12.80%	ROE	-36.10%	52W Range	35.40 - 121.16	Perf YTD	-25.07%
Dividend	-	P/FCF	-	EPS past 5Y	-12.30%	ROI	-33.30%	52W High	-43.36%	Beta	1.67
Dividend %	-	Quick Ratio	6.80	Sales past 5Y	66.80%	Gross Margin	-	52W Low	93.84%	ATR	4.43
Employees	279	Current Ratio	6.80	Sales Q/Q	143.60%	Oper. Margin	-	RSI (14)	43.06	Volatility	5.87% 5.10%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-65.10%	Profit Margin	-	Rel Volume	0.24	Prev Close	68.13
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 04 AMC	Payout	-	Avg Volume	996.96K	Price	68.62
Recom	1.90	SMA20	-2.53%	SMA50	-13.12%	SMA200	-20.42%	Volume	25,382	Change	0.72%

Aug-26-21

Initiated

Morgan Stanley

Equal-Weight

$77

Jun-07-21

Upgrade

H.C. Wainwright

Neutral → Buy

$120

May-07-21

Upgrade

Wedbush

Neutral → Outperform

$88

Apr-26-21

Resumed

Jefferies

Buy

$145

Feb-26-21

Initiated

BofA Securities

Buy

$115

Feb-26-21

Downgrade

Wedbush

Outperform → Neutral

Feb-11-21

Downgrade

Citigroup

Buy → Neutral

Jan-27-21

Resumed

H.C. Wainwright

Neutral

$108

May-13-20

Initiated

H.C. Wainwright

Buy

$42

Mar-04-20

Initiated

Barclays

Overweight

$40

Jan-09-20

Downgrade

BMO Capital Markets

Outperform → Market Perform

$22

Dec-30-19

Reiterated

Mizuho

Buy

$27 → $33

Dec-09-19

Upgrade

Wells Fargo

Market Perform → Outperform

Nov-12-19

Initiated

SunTrust

Buy

$25

Nov-06-19

Downgrade

Wells Fargo

Outperform → Market Perform

Oct-01-19

Initiated

Stifel

Buy

$27

Aug-09-19

Initiated

BTIG Research

Buy

$27

Jul-22-19

Initiated

Cantor Fitzgerald

Overweight

Jul-12-19

Initiated

Oppenheimer

Outperform

$27

Jun-13-19

Initiated

Mizuho

Buy

Sep-15-21 08:00AM	Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine Support GlobeNewswire
Sep-14-21 08:19AM	Recent Poor Results Have Made This Promising Cathie Wood Pick a Bargain Motley Fool
Sep-03-21 11:31AM	Why Is Fate Therapeutics (FATE) Down 21% Since Last Earnings Report? Zacks
Sep-02-21 04:01PM	Fate Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Aug-26-21 07:36AM	We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely Simply Wall St.
Aug-20-21 04:02PM	Fate Stock Collapses As Investors Question Durability Of Cancer 'Killers' Investor's Business Daily -21.74%
11:57AM	Why Fate Therapeutics Stock Is Sliding Today Motley Fool
06:36AM	Fate Therapeutics' Stem Cell-Derived NK Lymphoma Candidate Casts Doubt Over Durability Of Response Benzinga
05:54AM	Fate Therapeutics Stock Falls on Trial Data for Lymphoma Treatment TheStreet.com
Aug-19-21 04:01PM	Fate Therapeutics Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Programs for B-cell Lymphoma GlobeNewswire -5.90%
Aug-15-21 11:05AM	The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow Benzinga
Aug-06-21 04:31PM	Fate Therapeutics, inc (FATE) Q2 2021 Earnings Call Transcript Motley Fool
Aug-05-21 11:41AM	FATE Reports Wider-Than-Expected Q2 Loss, Beats on Revenues Zacks +11.44%
Aug-04-21 05:55PM	Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01PM	Fate Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Operational Progress GlobeNewswire
Aug-02-21 04:50PM	Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-Cell Therapy GlobeNewswire
Jul-28-21 03:04PM	Earnings Preview: Fate Therapeutics (FATE) Q2 Earnings Expected to Decline Zacks +5.84%
Jul-22-21 11:40AM	Did You See What Cathie Wood Bought on Wednesday? Motley Fool
Jul-16-21 08:00AM	Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-derived NK Cell Franchise for B-cell Lymphoma GlobeNewswire
Jul-15-21 04:01PM	Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2021 Financial Results GlobeNewswire
Jun-28-21 09:31AM	Hedge Funds Have Never Been This Bullish On Fate Therapeutics Inc (FATE) Insider Monkey +5.41%
Jun-15-21 08:00AM	Fate Therapeutics Appoints Mark Plavsic, DVM, PhD, RAC as Chief Technical Officer GlobeNewswire
Jun-04-21 03:06PM	Fate Therapeutics Stock is Trading Higher on Positive B-Cell Lymphoma Data at ASCO21 Benzinga +8.24%
11:32AM	Why Is Fate Therapeutics (FATE) Down 12.2% Since Last Earnings Report? Zacks
07:00AM	Fate Therapeutics Highlights Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma at 2021 ASCO Annual Meeting GlobeNewswire
Jun-02-21 09:40AM	10 Best Pharmaceutical Stocks to Buy According to Cathie Wood Insider Monkey
May-31-21 06:01AM	The Best Biotech Stocks to Buy With $500 Motley Fool
May-25-21 04:01PM	Fate Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
May-14-21 08:17AM	Fate Therapeutics' iPSC-Derived Cell Therapies Induce Leukemic Blast Clearance, Show Durable Remissions In AML Patients Benzinga +7.26%
May-13-21 04:01PM	Fate Therapeutics Announces Encouraging Interim Phase 1 Data for iPSC-derived NK Cell Programs in Relapsed / Refractory Acute Myeloid Leukemia GlobeNewswire
May-06-21 01:29PM	FATE Reports Wider-Than-Expected Q1 Loss, Beats on Revenues Zacks
11:01AM	Fate Therapeutics Inc (FATE) Q1 2021 Earnings Call Transcript Motley Fool
May-05-21 05:15PM	Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:01PM	Fate Therapeutics Reports First Quarter 2021 Financial Results and Highlights Operational Progress GlobeNewswire
03:15PM	Fate Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Apr-29-21 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2021 Financial Results GlobeNewswire -6.75%
Apr-27-21 04:31PM	Fate Therapeutics Announces Four Presentations at the 2021 ASGCT Annual Meeting GlobeNewswire
Apr-15-21 12:29PM	Natural Killer Cells and Other Promising Cancer Treatments Barrons.com
Apr-06-21 02:00PM	Is Fate Therapeutics Stock A Buy or Sell? Insider Monkey
Apr-02-21 06:20AM	3 of the Most Innovative Stocks to Buy Now Motley Fool
Mar-26-21 11:31AM	Fate Therapeutics (FATE) Down 9% Since Last Earnings Report: Can It Rebound? Zacks -8.10%
Mar-25-21 07:00AM	Fate Therapeutics Announces Retirement of Chief Scientific Officer after 12 Years of Service GlobeNewswire
05:55AM	2 Under-the-Radar Stocks Cathie Wood Loves That Could Be Huge Winners Motley Fool
Mar-08-21 07:00AM	Fate Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire -5.37%
Feb-27-21 09:23AM	15 Fastest Growing Biotech Companies in the US Insider Monkey
01:43AM	Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates Simply Wall St.
Feb-25-21 12:48PM	FATE Reports Wider-Than-Expected Q4 Loss on Higher Expenses Zacks -9.45%
03:30AM	Fate Therapeutics Inc (FATE) Q4 2020 Earnings Call Transcript Motley Fool
Feb-24-21 04:55PM	Fate Therapeutics: Q4 Earnings Insights Benzinga
04:01PM	Fate Therapeutics Reports Fourth Quarter 2020 Financial Results and Highlights Operational Progress GlobeNewswire
03:15PM	Fate Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-22-21 04:01PM	Fate Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference GlobeNewswire -8.37%
Feb-08-21 12:49AM	Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Could Be 26% Below Their Intrinsic Value Estimate Simply Wall St.
Jan-29-21 06:56AM	Got $5,000 and 5 Years to Wait? Buy These 5 Hot Biotech Stocks Now Motley Fool
Jan-28-21 06:42AM	2 Best Biotech Stocks to Buy in January Motley Fool
Jan-11-21 08:02AM	The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals Zacks
Jan-08-21 04:26PM	Fate Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants, and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
09:01AM	CRISPR Gene Editing Stocks Up After Intellia's Pipeline Update Zacks
08:50AM	Is the Options Market Predicting a Spike in Fate Therapeutics (FATE) Stock? Zacks
Jan-07-21 04:24PM	Genetics Stocks Pop After Intellia Offers Update For Gene-Editing Drugs Investor's Business Daily +17.48%
Jan-06-21 12:30AM	Fate Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire +15.06%
Jan-05-21 06:23AM	3 Biotech Stocks That Could Double Your Money in 2021 Motley Fool
Jan-04-21 04:01PM	Fate Therapeutics Announces Proposed Public Offering of $350 Million of Common Stock GlobeNewswire
Dec-30-20 10:42AM	The Zacks Analyst Blog Highlights: Moderna, Ultragenyx Pharma, Fate Therapeutics, Intellia Therapeutics, and Mersana Therapeutics Zacks
07:18AM	Here's a Cancer-Killing Stock to Buy for 2021 Motley Fool
Dec-29-20 09:37AM	5 Biotech Stocks That Have Gained More Than 200% in 2020 Zacks
Dec-28-20 10:43AM	FATE Surges More Than 152% in Three Months: Here's Why? Zacks
Dec-23-20 09:21AM	Here's Why Fate Therapeutics' Data Produced a 38% Jump in the Stock Price Motley Fool
Dec-22-20 04:30PM	Is FATE A Good Stock To Buy According To Hedge Funds? Insider Monkey +7.33%
Dec-09-20 08:42AM	Fate Therapeutics (FATE) Looks Good: Stock Adds 9.4% in Session Zacks -5.46%
Dec-08-20 01:22PM	Fate (FATE) Surges on Favorable Phase I Data on FT596 at ASH Zacks +9.35%
Dec-07-20 04:20PM	Here Are The Winners Of This Year's Biggest Blood Cancer Meeting Investor's Business Daily +37.80%
03:33PM	Fate Stock Soars After Novel Natural-Killer Treatment for Cancers Makes a Splash Barrons.com
12:39PM	Why Fate Therapeutics Stock Is Skyrocketing Today Motley Fool
10:00AM	Traders Sift Through Biotech Winners and Losers After Hematology Meeting Bloomberg
Dec-06-20 10:05AM	Fate Therapeutics Presents Patient Case Study Demonstrating Clinical Activity of FT596 in Refractory Diffuse Large B-cell Lymphoma GlobeNewswire
Dec-05-20 11:32AM	Why Is Fate Therapeutics (FATE) Up 21.8% Since Last Earnings Report? Zacks
Dec-04-20 04:01PM	Fate Therapeutics Reports Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma GlobeNewswire
10:43AM	Red-Hot Biotechs to Take Spotlight at Blood Disorder Meeting Bloomberg
Nov-30-20 08:00AM	Fate Therapeutics to Host Virtual Event at the 2020 ASH Annual Meeting GlobeNewswire
Nov-12-20 04:01PM	Fate Therapeutics Announces Participation in Upcoming Investor Conferences GlobeNewswire
Nov-10-20 05:54AM	Growth Investors: Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 25% Simply Wall St.
Nov-07-20 02:00AM	Fate Therapeutics Inc (FATE) Q3 2020 Earnings Call Transcript Motley Fool
Nov-05-20 06:05PM	Fate Therapeutics (FATE) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:01PM	Fate Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Operational Progress GlobeNewswire
03:45PM	Fate Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
08:00AM	Fate Therapeutics Announces Twelve Presentations at the 2020 ASH Annual Meeting GlobeNewswire
Nov-03-20 09:15AM	Were Hedge Funds Right About Loading Up On Fate Therapeutics Inc (FATE)? Insider Monkey
Nov-02-20 07:00AM	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2020 Financial Results GlobeNewswire
Oct-15-20 08:00AM	Fate Therapeutics Announces Presentations at the 2020 Society for Immunotherapy of Cancer Annual Meeting GlobeNewswire
Sep-30-20 08:00AM	Fate Therapeutics to Present at Jefferies Cell Therapy Virtual Summit GlobeNewswire
Sep-11-20 10:11AM	Hedge Funds Are Absolutely Crazy About Fate Therapeutics Inc (FATE) Insider Monkey +5.73%
Sep-04-20 08:00AM	Fate Therapeutics Announces September Investor Events GlobeNewswire
Aug-19-20 08:00AM	Fate Therapeutics Appoints Edward Dulac as Chief Financial Officer GlobeNewswire
Aug-11-20 08:19AM	What Kind Of Shareholders Own Fate Therapeutics, Inc. (NASDAQ:FATE)? Simply Wall St.
08:00AM	How Much Of Fate Therapeutics, Inc. (NASDAQ:FATE) Do Institutions Own? Simply Wall St.
Aug-05-20 05:55PM	Fate Therapeutics (FATE) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:01PM	Fate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational Progress GlobeNewswire
Aug-04-20 04:01PM	Fate Therapeutics to Present at the Wedbush PacGrow Healthcare Virtual Conference GlobeNewswire
Jul-29-20 04:01PM	Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2020 Financial Results GlobeNewswire

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors, as well as ProTmune for the treatment of hematologic malignancies and rare genetic disorders. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Valamehr Bahram	Chief Development Officer	Sep 13	Option Exercise	2.73	25,000	68,250	120,740	Sep 14 04:01 PM
Valamehr Bahram	Chief Development Officer	Sep 13	Sale	66.29	25,000	1,657,257	95,740	Sep 14 04:01 PM
Wolchko J Scott	President and CEO	Aug 19	Option Exercise	4.83	20,000	96,700	413,793	Aug 20 04:02 PM
Dulac Edward J III	Chief Financial Officer	Aug 19	Sale	88.26	3,474	306,602	54,539	Aug 20 04:01 PM
Wolchko J Scott	President and CEO	Aug 19	Sale	88.01	20,000	1,760,204	393,793	Aug 20 04:02 PM
Wolchko J Scott	President and CEO	Jul 23	Option Exercise	4.14	30,000	124,100	423,793	Jul 26 04:05 PM
Wolchko J Scott	President and CEO	Jul 23	Sale	85.28	30,000	2,558,538	393,793	Jul 26 04:05 PM
Wolchko J Scott	President and CEO	Jul 22	Option Exercise	2.73	30,000	81,900	423,793	Jul 26 04:05 PM
Wolchko J Scott	President and CEO	Jul 22	Sale	86.05	30,000	2,581,575	393,793	Jul 26 04:05 PM
Valamehr Bahram	Chief Development Officer	Jun 14	Option Exercise	2.84	25,000	70,997	120,740	Jun 16 04:26 PM
Valamehr Bahram	Chief Development Officer	Jun 14	Sale	89.32	25,000	2,233,045	95,740	Jun 16 04:26 PM
Wolchko J Scott	President and CEO	May 20	Option Exercise	4.83	20,000	96,700	413,793	May 24 04:01 PM
Wolchko J Scott	President and CEO	May 20	Sale	77.16	20,000	1,543,292	393,793	May 24 04:01 PM
Wolchko J Scott	President and CEO	Apr 23	Option Exercise	5.02	30,000	150,500	423,793	Apr 26 04:03 PM
Wolchko J Scott	President and CEO	Apr 23	Sale	85.24	30,000	2,557,284	393,793	Apr 26 04:03 PM
Wolchko J Scott	President and CEO	Apr 22	Option Exercise	2.73	30,000	81,900	423,793	Apr 26 04:03 PM
Wolchko J Scott	President and CEO	Apr 22	Sale	85.54	30,000	2,566,212	393,793	Apr 26 04:03 PM
Chu Yu-Waye	Senior VP Clinical Development	Apr 16	Sale	83.30	3,275	272,809	64,800	Apr 20 04:00 PM
TAHL CINDY	See Remarks	Apr 01	Option Exercise	3.21	30,000	96,199	138,048	Apr 02 06:03 PM
TAHL CINDY	See Remarks	Apr 01	Sale	83.81	30,000	2,514,329	108,048	Apr 02 06:03 PM
Valamehr Bahram	Chief Development Officer	Mar 15	Sale	92.35	25,000	2,308,772	95,740	Mar 16 04:05 PM
Shoemaker Daniel D	Chief Scientific Officer	Mar 08	Sale	81.74	25,000	2,043,428	73,020	Mar 09 04:02 PM
Wolchko J Scott	President and CEO	Feb 18	Option Exercise	6.62	20,000	132,400	413,793	Feb 19 04:07 PM
Wolchko J Scott	President and CEO	Feb 18	Sale	102.01	20,000	2,040,258	393,793	Feb 19 04:07 PM
Wolchko J Scott	President and CEO	Jan 22	Option Exercise	5.32	30,000	159,700	423,793	Jan 22 06:23 PM
Wolchko J Scott	President and CEO	Jan 22	Sale	98.29	30,000	2,948,611	393,793	Jan 22 06:23 PM
Wolchko J Scott	President and CEO	Jan 21	Option Exercise	2.73	30,000	81,900	423,793	Jan 22 06:23 PM
Wolchko J Scott	President and CEO	Jan 21	Sale	103.05	30,000	3,091,357	393,793	Jan 22 06:23 PM
TAHL CINDY	General Counsel and Secretary	Jan 19	Option Exercise	2.90	35,000	101,500	125,035	Jan 21 07:08 PM
TAHL CINDY	General Counsel and Secretary	Jan 19	Sale	114.76	35,000	4,016,639	90,035	Jan 21 07:08 PM
Shoemaker Daniel D	Chief Scientific Officer	Jan 11	Sale	110.81	3,253	360,477	83,609	Jan 12 08:38 PM
TAHL CINDY	General Counsel and Secretary	Jan 11	Sale	110.81	3,254	360,587	90,035	Jan 12 08:39 PM
Valamehr Bahram	Chief Development Officer	Jan 11	Sale	110.81	3,254	360,588	77,727	Jan 12 08:40 PM
Wolchko J Scott	President and CEO	Jan 11	Sale	110.81	8,587	951,556	350,562	Jan 12 08:41 PM
Redmile Group, LLC	Director	Jan 08	Buy	85.50	327,485	27,999,968	12,957,222	Jan 12 04:16 PM
Wolchko J Scott	President and CEO	Jan 08	Sale	117.10	60,820	7,122,217	359,149	Jan 12 08:41 PM
Valamehr Bahram	Chief Development Officer	Jan 08	Sale	117.10	6,230	729,552	80,981	Jan 12 08:40 PM
TAHL CINDY	General Counsel and Secretary	Jan 08	Sale	117.10	6,229	729,434	93,289	Jan 12 08:39 PM
Shoemaker Daniel D	Chief Scientific Officer	Jan 08	Sale	117.10	6,229	729,434	86,862	Jan 12 08:38 PM
Wolchko J Scott	President and CEO	Dec 17	Option Exercise	6.62	20,000	132,400	439,969	Dec 18 04:01 PM
Wolchko J Scott	President and CEO	Dec 17	Sale	91.82	20,000	1,836,352	419,969	Dec 18 04:01 PM
Valamehr Bahram	Chief Development Officer	Dec 14	Option Exercise	2.90	25,000	72,500	112,211	Dec 15 04:01 PM
Valamehr Bahram	Chief Development Officer	Dec 14	Sale	97.78	25,000	2,444,477	87,211	Dec 15 04:01 PM
Shoemaker Daniel D	Chief Scientific Officer	Nov 16	Sale	51.83	25,000	1,295,746	93,091	Nov 16 05:12 PM
Wolchko J Scott	President and CEO	Nov 13	Option Exercise	5.73	30,000	172,008	430,123	Nov 16 04:02 PM
Wolchko J Scott	President and CEO	Nov 13	Sale	51.03	30,000	1,530,900	419,969	Nov 16 04:02 PM
Wolchko J Scott	President and CEO	Nov 12	Option Exercise	2.73	30,000	81,900	449,969	Nov 16 04:02 PM
Wolchko J Scott	President and CEO	Nov 12	Sale	52.72	30,000	1,581,524	419,969	Nov 16 04:02 PM
TAHL CINDY	General Counsel and Secretary	Nov 05	Option Exercise	2.82	19,282	54,340	118,800	Nov 06 04:02 PM
TAHL CINDY	General Counsel and Secretary	Nov 05	Sale	50.63	19,282	976,252	99,518	Nov 06 04:02 PM
TAHL CINDY	General Counsel and Secretary	Nov 04	Option Exercise	2.73	51,519	140,647	151,037	Nov 06 04:02 PM
TAHL CINDY	General Counsel and Secretary	Nov 04	Sale	50.41	51,519	2,597,140	99,518	Nov 06 04:02 PM
TAHL CINDY	General Counsel and Secretary	Oct 16	Option Exercise	2.73	29,199	79,713	128,717	Oct 20 04:01 PM
TAHL CINDY	General Counsel and Secretary	Oct 16	Sale	50.25	29,199	1,467,212	99,518	Oct 20 04:01 PM
TAHL CINDY	General Counsel and Secretary	Oct 01	Option Exercise	2.73	35,000	95,550	134,518	Oct 02 04:01 PM
TAHL CINDY	General Counsel and Secretary	Oct 01	Sale	40.74	35,000	1,426,065	99,518	Oct 02 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience